Wells Fargo’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.4M | Sell |
50,353
-103,846
| -67% | -$24.3M | ﹤0.01% | 1945 |
|
|
2026
Q1 | $35.3M | Buy |
154,199
+120,419
| +356% | +$27M | 0.01% | 1154 |
|
|
2025
Q4 | $7.2M | Buy |
33,780
+2,110
| +7% | +$436K | ﹤0.01% | 2331 |
|
|
2025
Q3 | $6.3M | Buy |
31,670
+179
| +0.6% | +$33.4K | ﹤0.01% | 2387 |
|
|
2025
Q2 | $5.44M | Buy |
31,491
+7,410
| +31% | +$1.21M | ﹤0.01% | 2407 |
|
|
2025
Q1 | $3.75M | Buy |
24,081
+5,433
| +29% | +$776K | ﹤0.01% | 2640 |
|
|
2024
Q4 | $2.57M | Buy |
18,648
+1,971
| +12% | +$259K | ﹤0.01% | 3007 |
|
|
2024
Q3 | $2.49M | Buy |
16,677
+6,067
| +57% | +$819K | ﹤0.01% | 2880 |
|
|
2024
Q2 | $1.45M | Sell |
10,610
-451
| -4% | -$61.4K | ﹤0.01% | 3229 |
|
|
2024
Q1 | $1.67M | Buy |
11,061
+596
| +6% | +$85.1K | ﹤0.01% | 3117 |
|
|
2023
Q4 | $1.32M | Buy |
10,465
+530
| +5% | +$52.8K | ﹤0.01% | 3238 |
|
|
2023
Q3 | $930K | Sell |
9,935
-884
| -8% | -$82.7K | ﹤0.01% | 3382 |
|
|
2023
Q2 | $966K | Buy |
10,819
+87
| +0.8% | +$7.57K | ﹤0.01% | 3509 |
|
|
2023
Q1 | $1.15M | Sell |
10,732
-28
| -0.3% | -$3.2K | ﹤0.01% | 3279 |
|
|
2022
Q4 | $1.31M | Buy |
10,760
+1,512
| +16% | +$176K | ﹤0.01% | 3073 |
|
|
2022
Q3 | $954K | Sell |
9,248
-373
| -4% | -$35.4K | ﹤0.01% | 3274 |
|
|
2022
Q2 | $895K | Sell |
9,621
-52,281
| -84% | -$4.93M | ﹤0.01% | 3357 |
|
|
2022
Q1 | $7.26M | Buy |
61,902
+4,306
| +7% | +$499K | ﹤0.01% | 2114 |
|
|
2021
Q4 | $7.75M | Sell |
57,596
-288,445
| -83% | -$42.9M | ﹤0.01% | 2099 |
|
|
2021
Q3 | $55.2M | Buy |
346,041
+334,782
| +2,973% | +$45.8M | 0.01% | 999 |
|
|
2021
Q2 | $1.48M | Buy |
11,259
+3,082
| +38% | +$411K | ﹤0.01% | 3942 |
|
|
2021
Q1 | $1.05M | Buy |
8,177
+4,823
| +144% | +$733K | ﹤0.01% | 4207 |
|
|
2020
Q4 | $559K | Buy |
3,354
+445
| +15% | +$73.6K | ﹤0.01% | 4439 |
|
|
2020
Q3 | $449K | Sell |
2,909
-1,050
| -27% | -$151K | ﹤0.01% | 4424 |
|
|
2020
Q2 | $585K | Sell |
3,959
-2,050
| -34% | -$281K | ﹤0.01% | 4210 |
|
|
2020
Q1 | $677K | Buy |
6,009
+3,729
| +164% | +$485K | ﹤0.01% | 3802 |
|
|
2019
Q4 | $317K | Sell |
2,280
-1,606
| -41% | -$178K | ﹤0.01% | 4694 |
|
|
2019
Q3 | $374K | Sell |
3,886
-17,444
| -82% | -$1.95M | ﹤0.01% | 4573 |
|
|
2019
Q2 | $2.46M | Sell |
21,330
-4,587
| -18% | -$549K | ﹤0.01% | 3162 |
|
|
2019
Q1 | $3.05M | Buy |
25,917
+16,836
| +185% | +$1.47M | ﹤0.01% | 3011 |
|
|
2018
Q4 | $569K | Sell |
9,081
-26,015
| -74% | -$1.63M | ﹤0.01% | 4250 |
|
|
2018
Q3 | $2.49M | Buy |
35,096
+7,154
| +26% | +$492K | ﹤0.01% | 3233 |
|
|
2018
Q2 | $1.86M | Buy |
27,942
+2,286
| +9% | +$150K | ﹤0.01% | 3510 |
|
|
2018
Q1 | $1.68M | Sell |
25,656
-16,900
| -40% | -$950K | ﹤0.01% | 3507 |
|
|
2017
Q4 | $1.71M | Buy |
42,556
+12,480
| +41% | +$454K | ﹤0.01% | 3500 |
|
|
2017
Q3 | $1.09M | Buy |
30,076
+26,692
| +789% | +$766K | ﹤0.01% | 3784 |
|
|
2017
Q2 | $94K | Sell |
3,384
-1,716
| -34% | -$45.3K | ﹤0.01% | 5192 |
|
|
2017
Q1 | $143K | Sell |
5,100
-147
| -3% | -$3.71K | ﹤0.01% | 5010 |
|
|
2016
Q4 | $106K | Buy |
+5,247
| New | +$105K | ﹤0.01% | 5117 |
|
|
2015
Q2 | – | Sell |
-2,575
| Closed | -$45K | – | 6330 |
|
|
2015
Q1 | $45K | Buy |
+2,575
| New | +$46.8K | ﹤0.01% | 5051 |
|
Other funds holding ASND
RCM
ACA
JT
Wells Fargo's ASND Position: Q2 2026 in Review
Wells Fargo reduced its Ascendis Pharma A/S (ASND) stake by 67% in Q2 2026, selling an estimated $24.3M and leaving 50,353 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1945.
Wells Fargo first reported a position in ASND in Q1 2015 and has held it in 40 quarters since. The position peaked at $55.2M in Q3 2021. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- Wells Fargo held 50,353 shares of Ascendis Pharma A/S worth $13.4M as of Q2 2026.
- Wells Fargo sold 103,846 Ascendis Pharma A/S shares in Q2 2026, an estimated $24.3M.
- Ascendis Pharma A/S made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1945 holding.
- Wells Fargo first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 40 quarters since.
- Wells Fargo's Ascendis Pharma A/S position peaked at $55.2M in Q3 2021.
- 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.